Study compares point-of-care test card with PCR for feline hemoplasma

A new comparative study in Veterinary Sciences examines whether a commercial molecular point-of-care test, the Pluslife® Feline Hemotropic Mycoplasma nucleic acid test card, can stand up against conventional PCR when testing blood from sick cats. That matters because feline hemotropic mycoplasmosis remains a diagnostic challenge in practice: cats may present with anemia or nonspecific illness, blood smear review is notoriously insensitive, and confirmatory molecular testing often depends on outside laboratories. (pmc.ncbi.nlm.nih.gov)

The clinical backdrop is well established. Feline hemoplasmas, including Mycoplasma haemofelis, ‘Candidatus Mycoplasma haemominutum,’ and ‘Candidatus Mycoplasma turicensis,’ can infect red blood cells and are associated with variable pathogenicity. M. haemofelis is generally considered the most pathogenic of the major feline species, while detection of other hemoplasmas doesn’t always explain anemia on its own. Reviews and guideline documents have consistently emphasized that PCR, not smear cytology, is the preferred diagnostic approach, and that results should be interpreted in the context of hematologic findings and the cat’s overall presentation. (pmc.ncbi.nlm.nih.gov)

That’s the gap this paper is trying to address. The study’s stated aim was to assess the diagnostic performance of the Pluslife card and to measure how often feline hemotropic mycoplasma was detected among clinically ill cats. While the full article was not readily surfaced in search results during reporting, the abstract summary indicates the investigators directly compared the commercial test card with conventional PCR on blood samples from sick cats. The manufacturer positions Pluslife’s veterinary platform as a rapid nucleic-acid testing system for companion animal infectious disease panels, including feline hemotropic mycoplasma, built around its Mini Dock analyzer and disposable cards. (pluslife.com)

Outside this paper, the broader evidence base supports the need for better near-patient diagnostics, but also sets a high bar for interpretation. Auburn University’s molecular diagnostics service notes that older smear-based diagnosis has largely been superseded by molecular methods, and describes very high analytical sensitivity for PCR-based detection. Review articles similarly note that PCR can identify infection that cytology misses, and that blood should ideally be collected before antibiotic treatment begins. (vetmed.auburn.edu)

Industry context is also relevant here. Pluslife has published internal evaluations of other veterinary molecular assays, including a feline upper respiratory panel, reporting high agreement with qualitative PCR in that application. That doesn’t validate the hemotropic mycoplasma card on its own, but it suggests the company is building a broader in-clinic molecular testing portfolio aimed at faster infectious disease workups. Independent validation will be what matters most to clinicians deciding whether to trust and adopt the platform. (pluslife.com)

Why it matters: For veterinary professionals, this story is less about one organism and more about workflow. Hemoplasma cases can be clinically messy, especially when anemia overlaps with retroviral disease, flea exposure, immunosuppression, or coinfections. A reliable in-clinic molecular assay could help practices move more quickly from suspicion to evidence-based treatment and client communication with pet parents. But speed doesn’t remove the need for judgment: positive PCR-type results may reflect infection without proving causation, and species-level differences still matter when weighing how much a result explains the cat’s illness. (pmc.ncbi.nlm.nih.gov)

There’s also a stewardship angle. Faster confirmation could reduce reliance on empiric treatment alone, support earlier investigation of differential diagnoses in nonregenerative or atypical anemia, and potentially improve triage in emergency and critical care settings. At the same time, if commercial point-of-care molecular tools become more common, practices will need clarity on sensitivity, specificity, false-negative risk, cost, analyzer requirements, and whether confirmatory reference-lab testing remains advisable in borderline cases. Those are the implementation questions that often determine whether a promising diagnostic actually changes care. (onlinelibrary.wiley.com)

What to watch: Watch for the full study data to be cited more widely, for any independent commentary from feline internal medicine or clinical pathology specialists, and for follow-on studies comparing the Pluslife platform with quantitative PCR, species-specific assays, or real-world emergency practice workflows. (pmc.ncbi.nlm.nih.gov)